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ABSTRACT
Aims and background. Colorectal cancer is the second most common cause of can-
cer-related death in Europe and the United States. Several studies have evaluated the
immune response to colorectal cancer, with contradictory results. Some studies
showed that lymphocyte infiltration in colorectal cancer seemed to be an important
prognostic parameter, a finding not confirmed by other studies. Several studies
showed the gamma-delta T-cell receptor repertoire of intestinal adenocarcinoma. In
this study, we hypothesize that the presence of T cells with the T-cell receptor gamma
complex may play a particular role in carcinogenesis and tumor progression. 
Methods. A total of 58 patients with colon adenocarcinoma was included in the
analysis. We used the TNM staging system to grade colon cancer.
Results. Thirty samples (52.6%) revealed a polyclonal rearrangement of T-cell recep-
tor gamma. In the N0 cases, only 5 samples revealed a T-cell receptor gamma molec-
ular assessment; in N1/N2 cases, 25 revealed a T-cell receptor gamma molecular as-
sessment. 
Conclusions. The results showed statistical significance between the presence of T-
cell receptor gamma and N1/N2 stage lymph nodes (P = 0.001).
Introduction
Colorectal cancer is the second most common cause of cancer-related death in Eu-
rope and the United States. It is calculated that more than 350,000 new cases are di-
agnosed and, in Europe, approximately 200,000 patients die from this disease every
year1. Mortality rates for colon cancer have decreased during the past 10-15 years,
due to the early detection, the more effective screening programs, and because of the
adjuvant and neoadjuvant chemotherapeutic treatments that have led to a significant
increase in tumor response and median survival1,2.
Several studies have evaluated the immune response to colorectal cancer3-5. Results
of these studies are contradictory. Some studies have shown that lymphocyte infiltra-
tion in colorectal cancer seems to be an important prognostic parameter, but other
studies did not confirm such findings3-5.
Intraepithelial lymphocytes are T cells that reside between the epithelial cells and a
distinct cellular compartment. T cells can express different types of the T-cell recep-
tor (TCR). The TCR is a heterodimeric receptor that can be formed from two different
pairs of chains: the alpha and beta chains (alpha/beta TCR) or the gamma and delta
chains (gamma/delta TCR). In humans, 5-15% of the intraepithelial cells in the small
bowel and up to 40% in the colon express the gamma/delta TCR5-9.
Several studies have shown the gamma-delta TCR repertoire of intestinal adenocar-
cinoma. They found that most of these T cells rearrange the variable region V‰1 and
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display two distinct features3-5. The first feature is that
their TCR repertoire is highly restricted and stable over
time. Thus, despite the theoretical potential for generat-
ing an enormous number of different TCR transcripts, a
remarkably restricted repertoire is found within the in-
testinal T cells. The second feature is that highly com-
partmentalized T cells, expressing distinct TCR tran-
scripts, were found within different parts of the intes-
tine or the peripheral blood. These findings imply a
function that involves local activity of the cell against a
narrow repertoire of ligands. This important function of
the mucosal gamma-delta T-cell population is not com-
pletely known10-12.
These T cells play an important role in maintaining
host cell integrity. TCR-gamma expression in tumor-in-
filtrating lymphocytes is significantly lower than in nor-
mal tissue, suggesting T-cell localization in colon tu-
mors. Even though tumor cells express antigens that are
capable of activating a host immune response, colon
cancers still develop. It has been suggested that an inad-
equate T-cell response may in part be responsible for
this phenomenon. Colon cancer cell lines can also pro-
duce factors that, in turn, inhibit Tcell function5-9.
In the present study, we hypothesized that the pres-
ence of T cells with a TCR gamma complex may play a
particular role in carcinogenesis and tumor progres-
sion.
Patients and methods
Case selection
We selected tissue blocks of intestinal colon adeno-
carcinoma from the archives of the Department of Hu-
man Pathology and Oncology of the University of Flo-
rence. The specimens were obtained from 58 patients
with known follow-up, all of whom underwent surgical
radical colon resection at the Department of Surgical
Pathology of the University of Florence from 2002 to
2003. Any suspected lesions are examined with macro-
scopic and microscopic evaluation. Thirty-three pa-
tients were males and 25 were females, ranging in age
from 88 to 40 years (mean, 55). Informed consent was
obtained from every patient prior to surgery, and tumor
samples were collected during surgery. All the speci-
mens were analyzed by the same pathologist, and pa-
tients were divided according to the TNM classification.
We compared a group of patients according to TNM N0
(Figure 1) to a series of patient N1 and N2 of the pathol-
ogy (Figure 2) and evaluated the presence/absence of
gamma-delta TCR in intestinal adenocarcinoma.
DNA extraction and genetic analysis of TCR gamma
DNA was isolated from formalin-fixed, paraffin-em-
bedded tissue sections. After dewaxing and proteinase
K digestion, the DNA was heated to 96°C for 10 min to
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destroy proteinase K activity. The DNA was extracted us-
ing the “GenomicPrep Cells and Tissue DNA Isolation
Kit” (GE Healthcare, Buckinghamshire, UK) according
to the manufacturer’s protocol. DNAs were quantified
by spectrophotometry and the DNA fragmentation state
was evaluated by 2% agarose gel.
The polymerase chain reaction (PCR) assay for TCRγ
rearrangement was performed with the consensus
primers TVγ (5’-AGGGTTGTGTTGGAATCAGG–3’) and
TJγ (5’- CGTCGACAACAAGTGTTGTTCCAC –3’). The as-
say is a two-step PCR. The first reactions were carried
out in a volume of 20 µl, with 1.5 mM MgCl2, 0.125 mM
dNTPs, 2 pmol of TJγ primer and 1 U Taq polymerase
Figure 1 - Colon adenocarcinoma (hematoxylin-eosin. x10). The
figure shows a moderately well-differentiated, infiltrating adeno-
carcinoma of the colon.
Figure 2 - Colon adenocarcinoma (hematoxylin-eosin, x10). The
figure shows an undifferentiated, infiltrating adenocarcinoma of
the colon with irregulars glands.
(Applied Biosystems, Foster City, CA, USA) with 200-350
ng of DNA template. The cycle conditions were: 15 s at
94°C, 20 s at 58°C and 20 s at 72°C for 25 cycles.
Later on, 20 µl of fresh PCR reagents were added to
products of first amplification, at concentrations of 1.5
mM MgCl2, 0.375 mM dNTPs, 12 pmol of TJγ primer, 18
pmol of TVγ primer and 1 U Taq polymerase. The cycles
of this second amplification were 31 with the same pa-
rameters of the previous reaction.
PCR products were analyzed by 15% acrylamide gel
electrophoresis and visualized under UV illumination
after ethidium bromide staining. A broad smear can be
obtained from a sample with infiltration of polyclonal
reactive T cell. Instead, a discrete band suggests the
presence of a monoclonal T-lymphocyte proliferation. A
PCR not showing smears or bands after polyacrylamide
gel electrophoresis means the tissue does not contain T
lymphocytes.
Statistical analysis
The presence of TCR gamma/delta T cells in the two
groups of colon carcinoma (correlated with disease pro-
gression) was calculated according to the Wilcoxon
Mann-Whitney test. Data analysis was performed using
SPSS Version 11.0 (SPSS, Chicago, IL, USA) statistical
package. Fisher’s exact test was applied to statistical
analysis of amplification’s return. A P value ≤0.05 was
considered to be statistically significant.
Results
Overall, 58 patients with colon adenocarcinoma were
included in the analysis. We used the TNM staging sys-
tem to grade the colon cancer. There were 33 N0 pa-
tients, 13 N1 patients and 12 N2 patients. We compared
the 33 patients with N0 to the 25 patients with N1/N2
cancers. The molecular rearrangement of TCR gamma
was evaluated. In all cases, DNA extraction was success-
ful and the DNA fragmentation state was low. Thirty
samples (52.6%) revealed a polyclonal rearrangement of
TCR gamma (Figure 3). In the N0cases, only 5 samples
revealed a TCR gamma polyclonal rearrangement; in
the N1/N2 cases, 25 revealed a TCR gamma polyclonal
rearrangement (Figure 4). These results show statistical
significance between the presence of TCR gamma and
N1/N2 stage lymph nodes (P = 0.001). However, there
was no significant correlation between the presence of
TCR gamma, tumor extension and the presence of
metastasis (P = 0.06).
Discussion
Changes in cell surface receptor expression in gas-
trointestinal mucosa may play a role in the pathogene-
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sis of colon cancer. Activation of T lymphocytes is initi-
ated by binding of the TCR antigen (antigen: OK???).
TCR is a multimeric protein complex consisting of a
disulfide-linked gamma/delta heterodimer that is non-
covalently associated with the CD3 polypeptidic chains.
Whereas the alpha and beta proteins contain all of the
information necessary for antigen recognition, the CD3
molecules are responsible for signal transduction. The
immunoglobulin-like gamma chain, along with the
delta chain, is expressed at the surface of a subset of T
lymphocytes13-15.
Two different chain combinations of the TCR complex
are used for antigen recognition: TCR alpha/beta and
TCR gamma/delta. Gamma/delta cells share numerous
features with their alpha and beta counterparts but they
have several unique properties. Gamma and delta T
cells are more prominent in the skin and gastrointesti-
nal mucosa than in peripheral blood and conventional
Figure 3 - Ethidium bromide-stained polyacrylamide gel of PCR
products from colon adenocarcinoma (lanes 1-7), monoclonal
control (cutaneous T cell lymphoma) (lane 9) and polyclonal con-
trol (lichen planus) (lane 10). The DNA marker is shown in lane 8.
Figure 4 - The graph shows TCR-gamma presence in the different
disease stages. Five N0 cases (16%) and 25 N1/N2 cases (97%)
showed TCR-gamma expression.
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lymphoid organs. These T cells play an important role in
maintaining host cell integrity. TCR-gamma expression
in tumor-infiltrating lymphocytes is significantly higher
than in normal intestinal tissue, suggesting T cell local-
ization in colon tumors16-18.
Even though tumor cells express antigens that are ca-
pable of activating a host immune response, colon can-
cers still develop. It has been suggested that an inade-
quate T-cell response may in part be responsible for this
feature. Colon cancer cells can also produce factors that
modulate T-cell function. TCR-gamma/delta cells are
selectively and consistently localized in colon tumor tis-
sue19,20.
We evaluated the expression of TCR gamma in 58 pa-
tients with colon adenocarcinoma. The patients were
divided into two groups based on TNM stage: the first
group included N0 patients and the second group
N1/N2 patients. We detected TCR gamma in 30 cases
(53%). Twenty-one cases were N1 and 4 N2, and only 5
cases were N0. We observed that the presence of gam-
ma/delta T-cells was significantly correlated with dis-
ease progression (P = 0.001). In addition, our study con-
firmed that intratumor TCR has a prognostic role in ad-
vanced colon carcinoma.
We found a significant correlation between the pres-
ence of TCR gamma and N1/N2 positive lymph nodes
(P = 0.001). The characterization of tumor-specific anti-
gens showed that tumors may have antigen determi-
nants which are recognized by the immune system. A
recent study indicated that these antigens may be tu-
mor-specific peptides that are absent in all adult nor-
mal tissues except germline cells. Immunotherapy us-
ing adoptive cell transfer is a promising approach which
can result in the regression of bulky invasive cancer in
some patients.
As regards colon cancer, some studies have reported
that some colon carcinoma specimens showed a leuko-
cyte infiltrate. In addition, tumor-associated lympho-
cytes with polyclonal expansion were demonstrated in
colon cancer cell lines. In colon cancer patients, it
seems that the clinical outcome may depend on tumor
characteristics (stage of disease, residual disease, histo-
logic type and grade of differentiation) and on the host
response to cancer. The manipulation of immune
mechanisms may offer powerful therapeutic tools for
the treatment of colon cancer patients. In recent years,
several studies have focused on the possible use of T
cells to attack established tumors21,22.
In the present study, we observed a significant corre-
lation between the presence of TCR gamma and disease
in N1/N2-positive lymph nodes (53%), whereas N0 pa-
tients (47%) did not show gamma/delta T cells (P =
0.001). This finding (which we have evaluated for the
first time in the literature) suggests the presence of TCR
gamma may have a determinant prognostic role in
colon adenocarcinoma treatment. TCR gamma expres-
sion is associated with an advanced stage of the pathol-
ogy. A recent study showed that gamma/delta T cells, in-
volved in inflammatory responses, play a central role in
tissue damage.
Further studies are necessary to better understand
the negative prognostic role of gamma/delta T cells in
colon carcinoma. Nevertheless, these data emphasize
the importance of the immune host response to cancer
and the need to better study the immune mechanisms
in order to modulate therapeutic treatment of cancer.
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